- **Shree Ganesh Remedies is a chemistry-for-hire company - it invents and manufactures the complex molecules that sit inside other companies’ finished drugs, agrochemicals and electronics, but never sells a branded product of its own. Founded in 2004 by a chemist in Gujarat’s industrial belt and built one reaction technology at a time, the business has grown from a single small unit into a listed partner for over a hundred global pharmaceutical and specialty-chemical firms. The recurring approach is to master difficult, niche chemical reactions that few competitors can handle, then use that skill to win custom-synthesis contracts that evolve into long-term manufacturing relationships - a model that has moved the company from simple intermediates toward patented molecules and large-scale supply deals.** # Business segments A single engine with two faces - a pharmaceutical-intermediates heritage that still provides the bulk of revenue, and a specialty-chemicals practice that is rapidly taking over, both delivered through the same contract-research-and-manufacturing model and the same set of reaction technologies. ## 1. Pharmaceutical intermediates: the legacy molecule factory **The company makes the chemical building blocks for generic drugs - anti-psychotics, anti-depressants, cancer therapies - and sells them to API manufacturers who turn them into finished medicines.** - **Built on off-patent drug waves** - SGRL identifies molecules that are in clinical trials or already approved by regulators like the US-FDA and EU-FDA, develops the intermediate, and then promotes it to API makers who are preparing for the generic launch when the patent expires. That is how it has built a catalogue of approximately fifty (50) pharmaceutical intermediates since its inception in 2004. - **Small batches, many products** - production runs on a campaign basis in multi-purpose plants, meaning the same reactor can switch between different molecules for different customers, which suits the small volumes and high variety of the pharma-intermediate world. The human- and veterinary-health portfolio spans 32-plus products across 15 therapeutic areas, with anti-psychotic intermediates alone having contributed as much as 29% of total revenue in one year. - **Sticky, decade-long customers** - roughly 70% of the business comes from manufacturing and commercialising intermediates for the latest branded APIs, and many customer relationships have lasted more than ten years, which the company believes insulates it from revenue swings. The customer list is concentrated in Europe, followed by the UK, Japan, Singapore, Korea and the USA. - **Shrinking share, not shrinking volume** - this segment historically represented over 90% of revenue but now sits below 60%, not because pharma work is declining but because the specialty-chemicals side is growing faster. ## 2. Specialty and fine chemicals: the growth engine moving up the value chain **What began as an extension into agrochemical and polymer ingredients has become the company’s main growth story, with project sizes swelling and customers upgrading SGRL from backup supplier to preferred partner.** - **From small lots to industrial scale** - when the company entered specialty chemicals in 2010, typical projects were 20-50 tonnes a year; today they run at 80-100 tonnes, and the company is fielding inquiries for over 500 tonnes annually. That shift is pulling the segment toward more than 60% of revenue in the coming years. - **A regulatory lock on the European market** - SGRL has secured REACH registration for its key products, which means it is a registered preferred supplier in the European Union; since 2018, only registered entities can sell there, so the registration doubles as an entry barrier against unregistered rivals. - **Winning bigger roles with global names** - the company has advanced from third-supplier to second-supplier status for medium-sized projects for a global client, and it signed a memorandum of understanding with a leading Japanese customer for a specialty chemical with commercial supplies expected later in 2025. It also earned approved-source status for an agrochemical product destined for Europe, with commercialisation slated for the second quarter of calendar 2026. - **Eleven-plus products across four industries** - the segment generated revenue of ₹555.17 million from a portfolio of 11-plus products serving the aroma and health, agrochemical, polymer and electronics industries, with end uses that range from coatings and high-performance photography to food additives and oil and gas. ## 3. Contract research and manufacturing (CRAMS/CDMO): the business model that ties it together **Every product the company sells - whether a pharma intermediate or a specialty chemical - is made under a contract-research or contract-manufacturing agreement where the customer pays for development work and then for each unit produced.** - **Paid for the journey, not just the destination** - the CDMO offering covers the full lifecycle: route scouting, process development, pilot-scale production, technology transfer and finally commercial manufacturing, so the company earns revenue at multiple stages before a molecule ever reaches large-scale supply. - **Selective about what it takes on** - a product only enters the pipeline if it clears a checklist: it must meet internal margin benchmarks, fall within mastered chemistries, involve three or four different reaction types to deter competition, be backward-integrated for cost control, and either be complex enough for SGRL to handle alone or come with a technology transfer from the client. - **Per-unit pricing on shared assets** - commercial production runs on a campaign basis in the same multi-purpose plants used for pharma intermediates, with revenue earned on a per-unit pricing model; roughly 10-15% of the business comes from pure contract manufacturing projects. - **The India cost advantage** - the Indian CDMO sector operates with an EBITDA margin of roughly 35%, compared with about 20% in the West, which gives SGRL a structural pricing edge when bidding for global contracts. # Chemistry and technology backbone **The company’s real moat is not any single product but its ability to perform a wide range of difficult, hazardous and tightly controlled chemical reactions under one roof - a breadth that most peers cannot match.** - **More reaction types than the typical rival** - SGRL has mastered halogenation, high-pressure catalytic hydrogenation up to 40 bar, Friedel-Crafts alkylation, Grignard reactions and palladium-catalysed carbon-carbon coupling like Heck and Suzuki, among others; most competitors have deep expertise in only two or three domains. - **High-pressure capability as a differentiator** - the company is one of the few players in its space with high-pressure reaction capability up to 600 psi, which puts it in a niche position for chemistries that require forcing gases into liquids under extreme conditions. - **Thionyl chloride leadership** - SGRL describes itself as a global player in thionyl-chloride-based derivatives with integrated operations across the product chain, meaning it can take a single starting material through multiple value-added steps rather than buying intermediates from others. - **R&D that feeds the pipeline** - a 40-member R&D and process team, operating out of a DSIR-recognised lab with 18 fume hoods and a new pilot plant, spends 3-4% of revenue annually on developing downstream derivatives and finding China-substitute raw-material alternatives through backward integration. # Manufacturing infrastructure **Two adjacent plants in Gujarat’s chemical corridor, plus a greenfield site under construction at Dahej, give the company the reactor capacity and environmental permits to handle everything from gram-scale trials to hundred-tonne commercial campaigns.** - **Seven production blocks with room to grow** - the Ankleshwar site houses seven functional manufacturing blocks, with an eighth added in FY24 and a seventh block (the numbering reflects the order of construction) due for commissioning in the first half of FY27 at a projected capital cost of roughly ₹20 crores. The total operational area exceeds 190,000 square feet across two units on 36,500 square metres of land. - **A flexible equipment fleet** - the plant floor includes 35 glass-lined reactors up to 25,000 litres, 28 stainless-steel reactors up to 15,000 litres, three autoclave reactors capable of 40-bar pressure, nine dryers, and eight distillation setups that can pull a vacuum down to 1 millibar using short-path and thin-film technology. A pilot plant with 12 reactors and a total capacity of 6,900 litres serves double duty as a commercial facility for low-volume, high-value products. - **Dahej: the large-scale bet** - a 40,554-square-metre plot at Dahej, acquired in 2022, is being developed with common infrastructure and utilities for a phased, capital-intensive expansion aimed at the 500-tonne-plus inquiries the company is now receiving; specific projects are under non-disclosure agreements and cannot yet be disclosed. - **Effluent treatment as a licence to operate** - an in-house effluent treatment plant with a three-effect evaporator, an agitated thin-film dryer, a reverse-osmosis unit and biological aeration tanks allows the company to take on chemistries that generate unavoidable waste, which is a prerequisite for winning contracts from environmentally conscious global customers. # Group structure and partners **SGRL is a standalone listed entity with no operating subsidiaries, a tightly held promoter group, and a history of using temporary acquisition structures solely to secure land.** - **No operating subsidiaries** - the company prepares its financial statements on a stand-alone basis and has no joint ventures or associate companies. A wholly owned US subsidiary, SGRL USA INC, was incorporated in August 2023 to strengthen North American marketing, but had not commenced operations as of end-2023. - **Land acquired through a shell-company manoeuvre** - to obtain the Dahej leasehold plot, SGRL acquired a 100% stake in Akshar Jyot Private Limited and a 74% stake in Dhari Chemicals Limited in September 2021; once the leasehold rights were transferred and registered in SGRL’s name, both entities were sold to unrelated third parties in March 2022. - **Promoter-held and family-led** - the promoter and promoter group held 69.33% of equity as of March 2023, with the founding Kothia family - father Chandulal as Managing Director and sons Gunjan and Parth as Whole-Time Directors overseeing business development and finance respectively - occupying the key executive roles.